Dear Dr Crystal thank you once again for this update. Regarding the VRBPAC, the link to the Novavax presentation leads to the Moderna one. I think the right link is this:
Seems to me that a sensible decision would be to aprove a KP.2 formulation for the mRNA vaccines while, at the same time, allow the Novavax JN.1. The latter appears to induce a broad Th1 protection to the FLiRT subvariants and is an option for whoever prefers a protein vaccine. This might rise communication problems (protein vs. mRNA), but the public understands that the protection spectrum may vary accross different vaccine platforms.
Thanks Manuel for the link. I agree with you about the vaccines. Part of the benefit of the mRNA vaccines is that they can be produced over a shorter time frame than the protein based vaccines. It would be better to have the next vaccine to include JN.1 + F456L mutation based antigen because that is where the virus is going and also because F456L makes it more immune evasive. I agree that the JN.1 Novavax vaccine could be offered to those who prefer it.
Thank you.
Dear Dr Crystal thank you once again for this update. Regarding the VRBPAC, the link to the Novavax presentation leads to the Moderna one. I think the right link is this:
https://www.fda.gov/media/179143/download
Seems to me that a sensible decision would be to aprove a KP.2 formulation for the mRNA vaccines while, at the same time, allow the Novavax JN.1. The latter appears to induce a broad Th1 protection to the FLiRT subvariants and is an option for whoever prefers a protein vaccine. This might rise communication problems (protein vs. mRNA), but the public understands that the protection spectrum may vary accross different vaccine platforms.
Manuel
Thanks Manuel for the link. I agree with you about the vaccines. Part of the benefit of the mRNA vaccines is that they can be produced over a shorter time frame than the protein based vaccines. It would be better to have the next vaccine to include JN.1 + F456L mutation based antigen because that is where the virus is going and also because F456L makes it more immune evasive. I agree that the JN.1 Novavax vaccine could be offered to those who prefer it.